샘플 요청 목록

 카트 문의
시장보고서
상품코드
2143649

무좀 치료 시장

Tinea Pedis (Athlete´s Foot) Treatment
발행일: | 리서치사: 구분자 Market Glass, Inc. | 페이지 정보: 영문 472 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



가격
PDF & Excel (Single User License) help
PDF & Excel 보고서를 1명만 이용할 수 있는 라이선스입니다. 파일 내 텍스트의 복사 및 붙여넣기는 가능하지만, 표/그래프 등은 복사할 수 없습니다. 인쇄는 1회 가능하며, 인쇄물의 이용범위는 파일 이용범위와 동일합니다.
US $ 5,850 금액 안내 화살표 ￦ 7,914,000
PDF & Excel (Team License: Up to 10 users) help
PDF & Excel 보고서를 동일 기업 내 최대 10명까지 이용할 수 있는 라이선스입니다. 파일 내 텍스트의 복사 및 붙여넣기가 가능하지만, 표/그래프 등은 복사할 수 없습니다. 인쇄는 이용자 1명당 1회 가능하며, 인쇄물의 이용범위는 파일 이용범위와 동일합니다.
US $ 11,115 금액 안내 화살표 ￦ 15,037,000
PDF & Excel (Global License to Company and its Fully-owned Subsidiaries) help
PDF & Excel 보고서를 동일 기업 및 100% 자회사의 모든 분이 이용하실 수 있는 라이선스입니다. 인쇄는 1인당 1회 가능하며, 인쇄물의 이용범위는 파일 이용범위와 동일합니다.
US $ 17,550 금액 안내 화살표 ￦ 23,743,000
※ 부가세 별도
한글목차
영문목차
※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

세계의 무좀 치료 시장은 2032년까지 18억 달러에 이른다고 전망되고 있습니다.

2025년에 14억 달러로 평가된 세계의 무좀 치료 치료 시장은 2025년부터 2032년 분석 기간 동안 CAGR 3.4%로 성장하여 2032년까지 18억 달러에 이를 것으로 예상되고 있습니다. 본 보고서로 분석 대상이 되고 있는 부문 중 하나인 ' 아조르계 약제 '는 CAGR 4.0%를 나타내고, 분석 기간 종료시점까지 6억 8,930만 달러에 이를 것으로 예상되고 있습니다.' 아릴 아민/벤질 아민계 약제 ' 부문의 성장률은 분석 기간을 통해서 CAGR 2.3%로 추정되고 있습니다.

미국 시장은 3억 8,090만 달러로 평가되는 한편, 중국 시장은 CAGR 6.0%를 나타낼 것으로 예측됩니다.

미국의 무좀 치료 시장은 2025년에 3억 8,090만 달러로 평가되었습니다. 세계 제 2위 경제 규모를 자랑하는 중국은 2025년부터 2032년 분석 기간 동안 CAGR 6.0%로 성장을 지속하여, 2032년까지 시장 규모가 3억 5,400만 달러에 이를 것으로 예측됩니다. 기타 주목해야 할 지역 시장으로서는 일본과 캐나다를 들 수 있어 분석 기간 중에 각각 CAGR 1.5% 및 2.7%를 나타낼 것으로 예측됩니다. 유럽내에서는 독일이 CAGR 약 2.2%를 나타낼 것으로 예측됩니다.

무좀 치료 - 주요 동향 및 성장 촉진요인

무좀은 특히 따뜻하고 습한 환경에서 발 피부에 감염되는 흔한 진균 감염증입니다. 이 감염증은 그러한 환경에서 번식하는 피부사상균에 의해 유발되며, 가려움증, 작열감, 발가락 사이나 발바닥 피부의 갈라짐 등의 증상을 일으킵니다. 경우에 따라 수포가 생기거나 피부가 벗겨지기도 합니다. 무좀은 전염성이 매우 강하여 감염자와의 직접적인 접촉, 탈의실 바닥, 샤워실, 수영장 주변 등의 오염된 표면을 만짐으로써 퍼집니다. 치료에는 일반적으로 항진균제가 사용되며, 감염의 중증도에 따라 외용제로 바르거나 내복약으로 복용합니다. 경미한 경우에는 시판되는 항진균 크림, 파우더, 스프레이가 일반적으로 사용되지만, 더 중증이나 낫기 어려운 감염증의 경우에는 처방전이 필요한 약을 사용해야 할 수도 있습니다.

무좀 치료법의 발전으로 다양한 효과적인 선택지가 생겨나고 있습니다. 클로트리마졸, 미코나졸, 테르비나핀 등의 외용 항진균제는 널리 구할 수 있으며, 많은 환자에게 효과적입니다. 이러한 치료법은 진균의 세포막을 파괴하여 작용함으로써 진균을 사멸시키고, 추가적인 증식을 막습니다. 더 중증이나 광범위하게 퍼진 감염의 경우, 플루코나졸이나 이트라코나졸과 같은 경구용 항진균제가 처방되는 경우가 많습니다. 이러한 전신 요법은 외용 요법만으로는 효과를 볼 수 없는 환자에게 특히 유용합니다. 또한, 항진균제와 항염증 성분을 결합한 병용 요법의 개발로 인해 감염증 자체뿐만 아니라 가려움증이나 염증과 같은 관련 증상도 함께 다룰 수 있게 되어 치료 성과가 향상되었습니다. 발을 건조한 상태로 유지하고, 통기성이 좋은 신발을 신으며, 개인 용품을 다른 사람과 공유하지 않는 등의 예방 조치도 무좀의 관리와 예방에 중요합니다.

무좀 치료 시장의 성장은 몇 가지 요인에 의해 주도되고 있습니다. 진균 감염증과 그 건강에 미치는 영향에 대한 인식이 높아짐에 따라 효과적인 치료법에 대한 수요가 증가하고 있습니다. 약제의 제형 및 전달 시스템 분야의 기술적 진보로 인해 더 효율적이고 편의성이 높은 치료 옵션이 등장하여, 환자의 복약 순응도와 치료 성과가 향상되고 있습니다. 스포츠 및 야외 활동 참여 증가 등 무좀 확산에 기여하는 생활 습관 요인 증가도 시장 성장을 뒷받침하고 있습니다. 또한, 의료 인프라 확충과 일반의약품의 접근성 향상으로 인해 더 폭넓은 계층이 치료를 받기 쉬워지고 있습니다. 새로운 항진균제 개발과 병용 요법에 대한 지속적인 연구로 인해 치료 선택지는 계속해서 확대되고 있습니다. 제약 회사의 인식 제고 캠페인 및 판촉 활동과 같은 마케팅 전략 또한 소비자의 인식을 높이고, 이러한 치료법의 보급을 뒷받침하고 있습니다. 이러한 추세가 지속적으로 발전하는 가운데, 무좀 치료 시장은 지속적인 혁신과 개인 위생 및 헬스케어에 대한 관심 증가에 힘입어 지속적인 성장이 예상됩니다.

부문 :

약제 클래스별(아조르계, 아릴 아민/벤질 아민계, 포리엔계, 기타), 질환(지간형 족부백선, 족저형 족부백선, 수포성/염증성 족부백선), 투여 경로(경구투여, 외용 투여), 유통 채널(병원 약국, 소매 약국, 온라인 판매)

주요 기업

  • Alva-Amco Pharmacal Companies, Inc.
  • Bausch Health Companies Inc.
  • Bayer Consumer Health
  • Blueberry Therapeutics
  • Cipla Health
  • DermBiont
  • Eisai Co., Ltd.
  • Galderma SA
  • Glenmark Pharmaceuticals Inc.
  • Pfizer, Inc.

해당 분야의 전문가들의 관점을 바탕으로 합니다. 산업계, 기업, 학계에 걸친 분야 전문가들의 관점을 반영하여, 기존의 공개 설문조사를 뛰어넘는 맥락을 제공합니다.

시장의 초기 신호를 포착합니다. - 기존의 2차 조사에 완전히 반영되기 전에, 전문가 간의 대화, 기업의 동향, 시장과 관련된 논의를 통해 드러나는 변화를 추적합니다.

광범위하고 검증된 정보 기반을 활용합니다. - 컨퍼런스 세션, 기조 연설, 패널 토론, 블로그, 기업 공시 정보, 연차 보고서, 기관지 및 기타 검증된 정보원에서 얻은 인사이트를 통합하고 있습니다.

신호와 전략적 시장 방향성을 연결합니다. - 이러한 관점을 통합하여 시장이 어디로 향하고 있는지, 그 움직임을 주도하는 요인은 무엇인지, 그리고 전략에 있어 가장 중요할 가능성이 있는 동향은 무엇인지 파악합니다.

상세한 기업 정보를 제공합니다 - 시장 수준의 분석에 그치지 않고, 경쟁 환경에 참여하며 그 형성에 기여하고 있는 기업을 상세하게 검증합니다.

주요 지역 시장 점유율을 면밀히 검토합니다. - 단일 세계 시장 점유율 수치만으로는 전체적인 상황을 파악하기 어렵습니다. 경쟁 구도는 지역에 따라 크게 다를 수 있습니다. 분석상 관련성이 있는 경우, Market Glass의 보고서는 각 시장의 구조와 동향에 맞추어 상세도를 조정하여 주요 지역 시장 점유율 분석을 심층적으로 다룹니다.

목차

제1장 조사 방법

제2장 주요 요약

  • 시장 개요
  • 주요 기업
  • 시장 동향 및 성장 촉진요인
  • 세계 시장 전망

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 스페인
  • 러시아
  • 기타 유럽
  • 아시아태평양
  • 호주
  • 인도
  • 한국
  • 기타 아시아태평양
  • 라틴아메리카
  • 아르헨티나
  • 브라질
  • 멕시코
  • 기타 라틴아메리카
  • 중동
  • 이란
  • 이스라엘
  • 사우디아라비아
  • 아랍에미리트
  • 기타 중동
  • 아프리카

제4장 경쟁

KTH 26.10.14

Global Tinea Pedis (Athlete's Foot) Treatment Market to Reach US$1.8 Billion by 2032

The global market for Tinea Pedis (Athlete's Foot) Treatment estimated at US$1.4 Billion in the year 2025, is expected to reach US$1.8 Billion by 2032, growing at a CAGR of 3.4% over the analysis period 2025-2032. Azoles Drug Class, one of the segments analyzed in the report, is expected to record a 4.0% CAGR and reach US$689.3 Million by the end of the analysis period. Growth in the Allylamines / Benzylamines Drug Class segment is estimated at 2.3% CAGR over the analysis period.

The U.S. Market is Estimated at US$380.9 Million While China is Forecast to Grow at 6.0% CAGR

The Tinea Pedis (Athlete's Foot) Treatment market in the U.S. is estimated at US$380.9 Million in the year 2025. China, the world's second largest economy, is forecast to reach a projected market size of US$354.0 Million by the year 2032 trailing a CAGR of 6.0% over the analysis period 2025-2032. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.5% and 2.7% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 2.2% CAGR.

Tinea Pedis (Athlete's Foot) Treatment - Key Trends and Drivers

Tinea pedis, or athlete's foot, is a common fungal infection that affects the skin on the feet, particularly in warm and moist environments. This infection is caused by dermatophytes, fungi that thrive in such conditions, leading to symptoms like itching, burning, and cracked skin between the toes or on the soles of the feet. In some cases, the infection can cause blistering or peeling skin. Athlete's foot is highly contagious, spreading through direct contact with an infected individual or by touching contaminated surfaces, such as locker room floors, showers, and pool areas. Treatment typically involves antifungal medications, which can be applied topically or taken orally, depending on the severity of the infection. For mild cases, over-the-counter antifungal creams, powders, and sprays are commonly used, while more severe or persistent infections may require prescription-strength medications.

Advancements in the treatment of tinea pedis have led to a variety of effective options. Topical antifungal treatments like clotrimazole, miconazole, and terbinafine are widely accessible and effective for many patients. These treatments work by disrupting the cell membranes of the fungi, thereby killing them and preventing further growth. For more severe or widespread infections, oral antifungal medications such as fluconazole and itraconazole are often prescribed. These systemic treatments are particularly beneficial for patients who do not respond to topical therapies alone. Additionally, the development of combination therapies that include antifungal agents and anti-inflammatory ingredients has improved treatment outcomes by addressing both the infection and associated symptoms like itching and inflammation. Preventive measures, including keeping feet dry, wearing breathable footwear, and avoiding the sharing of personal items, are also important in managing and preventing athlete's foot.

The growth in the tinea pedis treatment market is driven by several factors. Increased awareness of fungal infections and their health impacts has led to a higher demand for effective treatments. Technological advancements in drug formulation and delivery systems have resulted in more efficient and convenient treatment options, improving patient compliance and outcomes. The rising prevalence of lifestyle factors that contribute to the spread of athlete's foot such as increased participation in sports and outdoor activities also fuels market growth. Additionally, the expansion of healthcare infrastructure and the availability of over-the-counter medications have made treatments more accessible to a wider population. The development of new antifungal agents and ongoing research into combination therapies continue to broaden the treatment landscape. Marketing strategies by pharmaceutical companies, including educational campaigns and promotions, have also heightened consumer awareness and driven the adoption of these treatments. As these trends continue to evolve, the tinea pedis treatment market is expected to see sustained growth, supported by ongoing innovations and an increasing focus on personal hygiene and preventive healthcare.

SCOPE OF STUDY:

The report analyzes the Tinea Pedis (Athlete's Foot) Treatment market by the following Segments, and Geographic Regions/Countries:

Segments:

Drug Class (Azoles Drug Class, Allylamines / Benzylamines Drug Class, Polyenes Drug Class, Other Drug Classes); Disease (Interdigital Tinea Pedis Disease, Plantar Disease, Vesicular / Inflammatory Disease); Administration Route (Oral Administration Route, Topical Administration Route); Distribution Channel (Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel, Online Distribution Channel)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

SELECT PLAYERS -

  • Alva-Amco Pharmacal Companies, Inc.
  • Bausch Health Companies Inc.
  • Bayer Consumer Health
  • Blueberry Therapeutics
  • Cipla Health
  • DermBiont
  • Eisai Co., Ltd.
  • Galderma SA
  • Glenmark Pharmaceuticals Inc.
  • Pfizer, Inc.

WHAT SETS THIS REPORT APART FROM OTHERS?

Grounded in Domain Expert Perspectives - Incorporates perspectives emerging from domain experts across industry, enterprise and academia, adding context beyond conventional published research.

Captures Early Market Signals - Tracks shifts emerging through expert conversations, company activity and market-relevant discussions before they are fully reflected in traditional secondary research.

Draws From a Broad, Validated Intelligence Base - Brings together insights from conference sessions, keynotes, panel discussions, blogs, corporate disclosures, annual reports, institutional publications and other validated sources.

Connects Signals With Strategic Market Direction - Synthesizes these perspectives to identify where the market is moving, what is driving that movement and which developments are likely to matter most for strategy.

Provides In-Depth Company Intelligence - Extends beyond market-level analysis to examine the companies participating in and shaping the competitive environment.

Market Share Is Examined Where It Matters - A single global market share figure rarely tells the full story. Competitive structures can vary significantly across geographies. Where analytically relevant, Market Glass reports extend market share analysis into major regions with the level of detail tailored to the structure and dynamics of each market.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Trade Shocks, Uncertainty, and the Structural Rewiring of the Global Economy
    • Global Economic Update
    • Tinea Pedis (Athlete's Foot) Treatment - Global Key Competitors Percentage Market Share in 2026 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for 43 Players Worldwide in 2026 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Increasing Awareness of Fungal Infections Expands Addressable Market Opportunity
    • Innovations in Drug Delivery Systems Strengthen Business Case for New Therapies
    • Rising Participation in Sports and Outdoor Activities Spurs Demand for Treatments
    • Enhanced Accessibility of Over-the-Counter Medications Drives Market Growth
    • Development of Combination Therapies Improves Treatment Outcomes
    • Expansion of Healthcare Infrastructure Accelerates Demand for Antifungal Products
    • Increasing Focus on Personal Hygiene Sustains Market Growth
    • Emergence of New Antifungal Agents Boosts Innovation
    • Integration of Preventive Measures and Treatment Products Expands Market Reach
    • Rising Consumer Preference for Natural and Organic Products Generates New Opportunities
    • Influence of Digital Health Platforms on Treatment Accessibility
    • Increasing Incidence of Drug-Resistant Fungal Strains Creates Challenges
    • Role of Online Pharmacies and E-Commerce Platforms in Expanding Market Access
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Tinea Pedis (Athlete's Foot) Treatment Market Analysis of Annual Sales in US$ Thousand for Years 2020 through 2032
    • TABLE 2: World Recent Past, Current & Future Analysis for Tinea Pedis (Athlete's Foot) Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2025 through 2032 and % CAGR
    • TABLE 3: World Historic Review for Tinea Pedis (Athlete's Foot) Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 4: World 13-Year Perspective for Tinea Pedis (Athlete's Foot) Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2020, 2026 & 2032
    • TABLE 5: World Recent Past, Current & Future Analysis for Azoles Drug Class by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2025 through 2032 and % CAGR
    • TABLE 6: World Historic Review for Azoles Drug Class by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 7: World 13-Year Perspective for Azoles Drug Class by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
    • TABLE 8: World Recent Past, Current & Future Analysis for Allylamines / Benzylamines Drug Class by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2025 through 2032 and % CAGR
    • TABLE 9: World Historic Review for Allylamines / Benzylamines Drug Class by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 10: World 13-Year Perspective for Allylamines / Benzylamines Drug Class by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
    • TABLE 11: World Recent Past, Current & Future Analysis for Polyenes Drug Class by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2025 through 2032 and % CAGR
    • TABLE 12: World Historic Review for Polyenes Drug Class by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 13: World 13-Year Perspective for Polyenes Drug Class by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
    • TABLE 14: World Recent Past, Current & Future Analysis for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2025 through 2032 and % CAGR
    • TABLE 15: World Historic Review for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 16: World 13-Year Perspective for Other Drug Classes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
    • TABLE 17: World Recent Past, Current & Future Analysis for Interdigital Tinea Pedis Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2025 through 2032 and % CAGR
    • TABLE 18: World Historic Review for Interdigital Tinea Pedis Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 19: World 13-Year Perspective for Interdigital Tinea Pedis Disease by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
    • TABLE 20: World Recent Past, Current & Future Analysis for Plantar Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2025 through 2032 and % CAGR
    • TABLE 21: World Historic Review for Plantar Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 22: World 13-Year Perspective for Plantar Disease by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
    • TABLE 23: World Recent Past, Current & Future Analysis for Vesicular / Inflammatory Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2025 through 2032 and % CAGR
    • TABLE 24: World Historic Review for Vesicular / Inflammatory Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 25: World 13-Year Perspective for Vesicular / Inflammatory Disease by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
    • TABLE 26: World Recent Past, Current & Future Analysis for Oral Administration Route by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2025 through 2032 and % CAGR
    • TABLE 27: World Historic Review for Oral Administration Route by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 28: World 13-Year Perspective for Oral Administration Route by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
    • TABLE 29: World Recent Past, Current & Future Analysis for Topical Administration Route by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2025 through 2032 and % CAGR
    • TABLE 30: World Historic Review for Topical Administration Route by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 31: World 13-Year Perspective for Topical Administration Route by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
    • TABLE 32: World Recent Past, Current & Future Analysis for Hospital Pharmacies Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2025 through 2032 and % CAGR
    • TABLE 33: World Historic Review for Hospital Pharmacies Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 34: World 13-Year Perspective for Hospital Pharmacies Distribution Channel by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
    • TABLE 35: World Recent Past, Current & Future Analysis for Retail Pharmacies Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2025 through 2032 and % CAGR
    • TABLE 36: World Historic Review for Retail Pharmacies Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 37: World 13-Year Perspective for Retail Pharmacies Distribution Channel by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
    • TABLE 38: World Recent Past, Current & Future Analysis for Online Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2025 through 2032 and % CAGR
    • TABLE 39: World Historic Review for Online Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 40: World 13-Year Perspective for Online Distribution Channel by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020, 2026 & 2032

III. MARKET ANALYSIS

  • UNITED STATES
    • Tinea Pedis (Athlete's Foot) Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2026 (E)
    • TABLE 41: USA Recent Past, Current & Future Analysis for Tinea Pedis (Athlete's Foot) Treatment by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 42: USA Historic Review for Tinea Pedis (Athlete's Foot) Treatment by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 43: USA 13-Year Perspective for Tinea Pedis (Athlete's Foot) Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Distribution Channel for the Years 2020, 2026 & 2032
    • TABLE 44: USA Recent Past, Current & Future Analysis for Tinea Pedis (Athlete's Foot) Treatment by Drug Class - Azoles Drug Class, Allylamines / Benzylamines Drug Class, Polyenes Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 45: USA Historic Review for Tinea Pedis (Athlete's Foot) Treatment by Drug Class - Azoles Drug Class, Allylamines / Benzylamines Drug Class, Polyenes Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 46: USA 13-Year Perspective for Tinea Pedis (Athlete's Foot) Treatment by Drug Class - Percentage Breakdown of Value Sales for Azoles Drug Class, Allylamines / Benzylamines Drug Class, Polyenes Drug Class and Other Drug Classes for the Years 2020, 2026 & 2032
    • TABLE 47: USA Recent Past, Current & Future Analysis for Tinea Pedis (Athlete's Foot) Treatment by Disease - Interdigital Tinea Pedis Disease, Plantar Disease and Vesicular / Inflammatory Disease - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 48: USA Historic Review for Tinea Pedis (Athlete's Foot) Treatment by Disease - Interdigital Tinea Pedis Disease, Plantar Disease and Vesicular / Inflammatory Disease Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 49: USA 13-Year Perspective for Tinea Pedis (Athlete's Foot) Treatment by Disease - Percentage Breakdown of Value Sales for Interdigital Tinea Pedis Disease, Plantar Disease and Vesicular / Inflammatory Disease for the Years 2020, 2026 & 2032
    • TABLE 50: USA Recent Past, Current & Future Analysis for Tinea Pedis (Athlete's Foot) Treatment by Administration Route - Oral Administration Route and Topical Administration Route - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 51: USA Historic Review for Tinea Pedis (Athlete's Foot) Treatment by Administration Route - Oral Administration Route and Topical Administration Route Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 52: USA 13-Year Perspective for Tinea Pedis (Athlete's Foot) Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration Route and Topical Administration Route for the Years 2020, 2026 & 2032
  • CANADA
    • TABLE 53: Canada Recent Past, Current & Future Analysis for Tinea Pedis (Athlete's Foot) Treatment by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 54: Canada Historic Review for Tinea Pedis (Athlete's Foot) Treatment by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 55: Canada 13-Year Perspective for Tinea Pedis (Athlete's Foot) Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Distribution Channel for the Years 2020, 2026 & 2032
    • TABLE 56: Canada Recent Past, Current & Future Analysis for Tinea Pedis (Athlete's Foot) Treatment by Drug Class - Azoles Drug Class, Allylamines / Benzylamines Drug Class, Polyenes Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 57: Canada Historic Review for Tinea Pedis (Athlete's Foot) Treatment by Drug Class - Azoles Drug Class, Allylamines / Benzylamines Drug Class, Polyenes Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 58: Canada 13-Year Perspective for Tinea Pedis (Athlete's Foot) Treatment by Drug Class - Percentage Breakdown of Value Sales for Azoles Drug Class, Allylamines / Benzylamines Drug Class, Polyenes Drug Class and Other Drug Classes for the Years 2020, 2026 & 2032
    • TABLE 59: Canada Recent Past, Current & Future Analysis for Tinea Pedis (Athlete's Foot) Treatment by Disease - Interdigital Tinea Pedis Disease, Plantar Disease and Vesicular / Inflammatory Disease - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 60: Canada Historic Review for Tinea Pedis (Athlete's Foot) Treatment by Disease - Interdigital Tinea Pedis Disease, Plantar Disease and Vesicular / Inflammatory Disease Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 61: Canada 13-Year Perspective for Tinea Pedis (Athlete's Foot) Treatment by Disease - Percentage Breakdown of Value Sales for Interdigital Tinea Pedis Disease, Plantar Disease and Vesicular / Inflammatory Disease for the Years 2020, 2026 & 2032
    • TABLE 62: Canada Recent Past, Current & Future Analysis for Tinea Pedis (Athlete's Foot) Treatment by Administration Route - Oral Administration Route and Topical Administration Route - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 63: Canada Historic Review for Tinea Pedis (Athlete's Foot) Treatment by Administration Route - Oral Administration Route and Topical Administration Route Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 64: Canada 13-Year Perspective for Tinea Pedis (Athlete's Foot) Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration Route and Topical Administration Route for the Years 2020, 2026 & 2032
  • JAPAN
    • Tinea Pedis (Athlete's Foot) Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2026 (E)
    • TABLE 65: Japan Recent Past, Current & Future Analysis for Tinea Pedis (Athlete's Foot) Treatment by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 66: Japan Historic Review for Tinea Pedis (Athlete's Foot) Treatment by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 67: Japan 13-Year Perspective for Tinea Pedis (Athlete's Foot) Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Distribution Channel for the Years 2020, 2026 & 2032
    • TABLE 68: Japan Recent Past, Current & Future Analysis for Tinea Pedis (Athlete's Foot) Treatment by Drug Class - Azoles Drug Class, Allylamines / Benzylamines Drug Class, Polyenes Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 69: Japan Historic Review for Tinea Pedis (Athlete's Foot) Treatment by Drug Class - Azoles Drug Class, Allylamines / Benzylamines Drug Class, Polyenes Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 70: Japan 13-Year Perspective for Tinea Pedis (Athlete's Foot) Treatment by Drug Class - Percentage Breakdown of Value Sales for Azoles Drug Class, Allylamines / Benzylamines Drug Class, Polyenes Drug Class and Other Drug Classes for the Years 2020, 2026 & 2032
    • TABLE 71: Japan Recent Past, Current & Future Analysis for Tinea Pedis (Athlete's Foot) Treatment by Disease - Interdigital Tinea Pedis Disease, Plantar Disease and Vesicular / Inflammatory Disease - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 72: Japan Historic Review for Tinea Pedis (Athlete's Foot) Treatment by Disease - Interdigital Tinea Pedis Disease, Plantar Disease and Vesicular / Inflammatory Disease Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 73: Japan 13-Year Perspective for Tinea Pedis (Athlete's Foot) Treatment by Disease - Percentage Breakdown of Value Sales for Interdigital Tinea Pedis Disease, Plantar Disease and Vesicular / Inflammatory Disease for the Years 2020, 2026 & 2032
    • TABLE 74: Japan Recent Past, Current & Future Analysis for Tinea Pedis (Athlete's Foot) Treatment by Administration Route - Oral Administration Route and Topical Administration Route - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 75: Japan Historic Review for Tinea Pedis (Athlete's Foot) Treatment by Administration Route - Oral Administration Route and Topical Administration Route Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 76: Japan 13-Year Perspective for Tinea Pedis (Athlete's Foot) Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration Route and Topical Administration Route for the Years 2020, 2026 & 2032
  • CHINA
    • Tinea Pedis (Athlete's Foot) Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2026 (E)
    • TABLE 77: China Recent Past, Current & Future Analysis for Tinea Pedis (Athlete's Foot) Treatment by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 78: China Historic Review for Tinea Pedis (Athlete's Foot) Treatment by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 79: China 13-Year Perspective for Tinea Pedis (Athlete's Foot) Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Distribution Channel for the Years 2020, 2026 & 2032
    • TABLE 80: China Recent Past, Current & Future Analysis for Tinea Pedis (Athlete's Foot) Treatment by Drug Class - Azoles Drug Class, Allylamines / Benzylamines Drug Class, Polyenes Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 81: China Historic Review for Tinea Pedis (Athlete's Foot) Treatment by Drug Class - Azoles Drug Class, Allylamines / Benzylamines Drug Class, Polyenes Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 82: China 13-Year Perspective for Tinea Pedis (Athlete's Foot) Treatment by Drug Class - Percentage Breakdown of Value Sales for Azoles Drug Class, Allylamines / Benzylamines Drug Class, Polyenes Drug Class and Other Drug Classes for the Years 2020, 2026 & 2032
    • TABLE 83: China Recent Past, Current & Future Analysis for Tinea Pedis (Athlete's Foot) Treatment by Disease - Interdigital Tinea Pedis Disease, Plantar Disease and Vesicular / Inflammatory Disease - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 84: China Historic Review for Tinea Pedis (Athlete's Foot) Treatment by Disease - Interdigital Tinea Pedis Disease, Plantar Disease and Vesicular / Inflammatory Disease Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 85: China 13-Year Perspective for Tinea Pedis (Athlete's Foot) Treatment by Disease - Percentage Breakdown of Value Sales for Interdigital Tinea Pedis Disease, Plantar Disease and Vesicular / Inflammatory Disease for the Years 2020, 2026 & 2032
    • TABLE 86: China Recent Past, Current & Future Analysis for Tinea Pedis (Athlete's Foot) Treatment by Administration Route - Oral Administration Route and Topical Administration Route - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 87: China Historic Review for Tinea Pedis (Athlete's Foot) Treatment by Administration Route - Oral Administration Route and Topical Administration Route Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 88: China 13-Year Perspective for Tinea Pedis (Athlete's Foot) Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration Route and Topical Administration Route for the Years 2020, 2026 & 2032
  • EUROPE
    • Tinea Pedis (Athlete's Foot) Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2026 (E)
    • TABLE 89: Europe Recent Past, Current & Future Analysis for Tinea Pedis (Athlete's Foot) Treatment by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 90: Europe Historic Review for Tinea Pedis (Athlete's Foot) Treatment by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 91: Europe 13-Year Perspective for Tinea Pedis (Athlete's Foot) Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Distribution Channel for the Years 2020, 2026 & 2032
    • TABLE 92: Europe Recent Past, Current & Future Analysis for Tinea Pedis (Athlete's Foot) Treatment by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2025 through 2032 and % CAGR
    • TABLE 93: Europe Historic Review for Tinea Pedis (Athlete's Foot) Treatment by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 94: Europe 13-Year Perspective for Tinea Pedis (Athlete's Foot) Treatment by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2020, 2026 & 2032
    • TABLE 95: Europe Recent Past, Current & Future Analysis for Tinea Pedis (Athlete's Foot) Treatment by Drug Class - Azoles Drug Class, Allylamines / Benzylamines Drug Class, Polyenes Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 96: Europe Historic Review for Tinea Pedis (Athlete's Foot) Treatment by Drug Class - Azoles Drug Class, Allylamines / Benzylamines Drug Class, Polyenes Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 97: Europe 13-Year Perspective for Tinea Pedis (Athlete's Foot) Treatment by Drug Class - Percentage Breakdown of Value Sales for Azoles Drug Class, Allylamines / Benzylamines Drug Class, Polyenes Drug Class and Other Drug Classes for the Years 2020, 2026 & 2032
    • TABLE 98: Europe Recent Past, Current & Future Analysis for Tinea Pedis (Athlete's Foot) Treatment by Disease - Interdigital Tinea Pedis Disease, Plantar Disease and Vesicular / Inflammatory Disease - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 99: Europe Historic Review for Tinea Pedis (Athlete's Foot) Treatment by Disease - Interdigital Tinea Pedis Disease, Plantar Disease and Vesicular / Inflammatory Disease Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 100: Europe 13-Year Perspective for Tinea Pedis (Athlete's Foot) Treatment by Disease - Percentage Breakdown of Value Sales for Interdigital Tinea Pedis Disease, Plantar Disease and Vesicular / Inflammatory Disease for the Years 2020, 2026 & 2032
    • TABLE 101: Europe Recent Past, Current & Future Analysis for Tinea Pedis (Athlete's Foot) Treatment by Administration Route - Oral Administration Route and Topical Administration Route - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 102: Europe Historic Review for Tinea Pedis (Athlete's Foot) Treatment by Administration Route - Oral Administration Route and Topical Administration Route Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 103: Europe 13-Year Perspective for Tinea Pedis (Athlete's Foot) Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration Route and Topical Administration Route for the Years 2020, 2026 & 2032
  • FRANCE
    • Tinea Pedis (Athlete's Foot) Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2026 (E)
    • TABLE 104: France Recent Past, Current & Future Analysis for Tinea Pedis (Athlete's Foot) Treatment by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 105: France Historic Review for Tinea Pedis (Athlete's Foot) Treatment by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 106: France 13-Year Perspective for Tinea Pedis (Athlete's Foot) Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Distribution Channel for the Years 2020, 2026 & 2032
    • TABLE 107: France Recent Past, Current & Future Analysis for Tinea Pedis (Athlete's Foot) Treatment by Drug Class - Azoles Drug Class, Allylamines / Benzylamines Drug Class, Polyenes Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 108: France Historic Review for Tinea Pedis (Athlete's Foot) Treatment by Drug Class - Azoles Drug Class, Allylamines / Benzylamines Drug Class, Polyenes Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 109: France 13-Year Perspective for Tinea Pedis (Athlete's Foot) Treatment by Drug Class - Percentage Breakdown of Value Sales for Azoles Drug Class, Allylamines / Benzylamines Drug Class, Polyenes Drug Class and Other Drug Classes for the Years 2020, 2026 & 2032
    • TABLE 110: France Recent Past, Current & Future Analysis for Tinea Pedis (Athlete's Foot) Treatment by Disease - Interdigital Tinea Pedis Disease, Plantar Disease and Vesicular / Inflammatory Disease - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 111: France Historic Review for Tinea Pedis (Athlete's Foot) Treatment by Disease - Interdigital Tinea Pedis Disease, Plantar Disease and Vesicular / Inflammatory Disease Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 112: France 13-Year Perspective for Tinea Pedis (Athlete's Foot) Treatment by Disease - Percentage Breakdown of Value Sales for Interdigital Tinea Pedis Disease, Plantar Disease and Vesicular / Inflammatory Disease for the Years 2020, 2026 & 2032
    • TABLE 113: France Recent Past, Current & Future Analysis for Tinea Pedis (Athlete's Foot) Treatment by Administration Route - Oral Administration Route and Topical Administration Route - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 114: France Historic Review for Tinea Pedis (Athlete's Foot) Treatment by Administration Route - Oral Administration Route and Topical Administration Route Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 115: France 13-Year Perspective for Tinea Pedis (Athlete's Foot) Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration Route and Topical Administration Route for the Years 2020, 2026 & 2032
  • GERMANY
    • Tinea Pedis (Athlete's Foot) Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2026 (E)
    • TABLE 116: Germany Recent Past, Current & Future Analysis for Tinea Pedis (Athlete's Foot) Treatment by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 117: Germany Historic Review for Tinea Pedis (Athlete's Foot) Treatment by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 118: Germany 13-Year Perspective for Tinea Pedis (Athlete's Foot) Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Distribution Channel for the Years 2020, 2026 & 2032
    • TABLE 119: Germany Recent Past, Current & Future Analysis for Tinea Pedis (Athlete's Foot) Treatment by Drug Class - Azoles Drug Class, Allylamines / Benzylamines Drug Class, Polyenes Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 120: Germany Historic Review for Tinea Pedis (Athlete's Foot) Treatment by Drug Class - Azoles Drug Class, Allylamines / Benzylamines Drug Class, Polyenes Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 121: Germany 13-Year Perspective for Tinea Pedis (Athlete's Foot) Treatment by Drug Class - Percentage Breakdown of Value Sales for Azoles Drug Class, Allylamines / Benzylamines Drug Class, Polyenes Drug Class and Other Drug Classes for the Years 2020, 2026 & 2032
    • TABLE 122: Germany Recent Past, Current & Future Analysis for Tinea Pedis (Athlete's Foot) Treatment by Disease - Interdigital Tinea Pedis Disease, Plantar Disease and Vesicular / Inflammatory Disease - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 123: Germany Historic Review for Tinea Pedis (Athlete's Foot) Treatment by Disease - Interdigital Tinea Pedis Disease, Plantar Disease and Vesicular / Inflammatory Disease Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 124: Germany 13-Year Perspective for Tinea Pedis (Athlete's Foot) Treatment by Disease - Percentage Breakdown of Value Sales for Interdigital Tinea Pedis Disease, Plantar Disease and Vesicular / Inflammatory Disease for the Years 2020, 2026 & 2032
    • TABLE 125: Germany Recent Past, Current & Future Analysis for Tinea Pedis (Athlete's Foot) Treatment by Administration Route - Oral Administration Route and Topical Administration Route - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 126: Germany Historic Review for Tinea Pedis (Athlete's Foot) Treatment by Administration Route - Oral Administration Route and Topical Administration Route Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 127: Germany 13-Year Perspective for Tinea Pedis (Athlete's Foot) Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration Route and Topical Administration Route for the Years 2020, 2026 & 2032
  • ITALY
    • TABLE 128: Italy Recent Past, Current & Future Analysis for Tinea Pedis (Athlete's Foot) Treatment by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 129: Italy Historic Review for Tinea Pedis (Athlete's Foot) Treatment by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 130: Italy 13-Year Perspective for Tinea Pedis (Athlete's Foot) Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Distribution Channel for the Years 2020, 2026 & 2032
    • TABLE 131: Italy Recent Past, Current & Future Analysis for Tinea Pedis (Athlete's Foot) Treatment by Drug Class - Azoles Drug Class, Allylamines / Benzylamines Drug Class, Polyenes Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 132: Italy Historic Review for Tinea Pedis (Athlete's Foot) Treatment by Drug Class - Azoles Drug Class, Allylamines / Benzylamines Drug Class, Polyenes Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 133: Italy 13-Year Perspective for Tinea Pedis (Athlete's Foot) Treatment by Drug Class - Percentage Breakdown of Value Sales for Azoles Drug Class, Allylamines / Benzylamines Drug Class, Polyenes Drug Class and Other Drug Classes for the Years 2020, 2026 & 2032
    • TABLE 134: Italy Recent Past, Current & Future Analysis for Tinea Pedis (Athlete's Foot) Treatment by Disease - Interdigital Tinea Pedis Disease, Plantar Disease and Vesicular / Inflammatory Disease - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 135: Italy Historic Review for Tinea Pedis (Athlete's Foot) Treatment by Disease - Interdigital Tinea Pedis Disease, Plantar Disease and Vesicular / Inflammatory Disease Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 136: Italy 13-Year Perspective for Tinea Pedis (Athlete's Foot) Treatment by Disease - Percentage Breakdown of Value Sales for Interdigital Tinea Pedis Disease, Plantar Disease and Vesicular / Inflammatory Disease for the Years 2020, 2026 & 2032
    • TABLE 137: Italy Recent Past, Current & Future Analysis for Tinea Pedis (Athlete's Foot) Treatment by Administration Route - Oral Administration Route and Topical Administration Route - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 138: Italy Historic Review for Tinea Pedis (Athlete's Foot) Treatment by Administration Route - Oral Administration Route and Topical Administration Route Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 139: Italy 13-Year Perspective for Tinea Pedis (Athlete's Foot) Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration Route and Topical Administration Route for the Years 2020, 2026 & 2032
  • UNITED KINGDOM
    • Tinea Pedis (Athlete's Foot) Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2026 (E)
    • TABLE 140: UK Recent Past, Current & Future Analysis for Tinea Pedis (Athlete's Foot) Treatment by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 141: UK Historic Review for Tinea Pedis (Athlete's Foot) Treatment by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 142: UK 13-Year Perspective for Tinea Pedis (Athlete's Foot) Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Distribution Channel for the Years 2020, 2026 & 2032
    • TABLE 143: UK Recent Past, Current & Future Analysis for Tinea Pedis (Athlete's Foot) Treatment by Drug Class - Azoles Drug Class, Allylamines / Benzylamines Drug Class, Polyenes Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 144: UK Historic Review for Tinea Pedis (Athlete's Foot) Treatment by Drug Class - Azoles Drug Class, Allylamines / Benzylamines Drug Class, Polyenes Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 145: UK 13-Year Perspective for Tinea Pedis (Athlete's Foot) Treatment by Drug Class - Percentage Breakdown of Value Sales for Azoles Drug Class, Allylamines / Benzylamines Drug Class, Polyenes Drug Class and Other Drug Classes for the Years 2020, 2026 & 2032
    • TABLE 146: UK Recent Past, Current & Future Analysis for Tinea Pedis (Athlete's Foot) Treatment by Disease - Interdigital Tinea Pedis Disease, Plantar Disease and Vesicular / Inflammatory Disease - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 147: UK Historic Review for Tinea Pedis (Athlete's Foot) Treatment by Disease - Interdigital Tinea Pedis Disease, Plantar Disease and Vesicular / Inflammatory Disease Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 148: UK 13-Year Perspective for Tinea Pedis (Athlete's Foot) Treatment by Disease - Percentage Breakdown of Value Sales for Interdigital Tinea Pedis Disease, Plantar Disease and Vesicular / Inflammatory Disease for the Years 2020, 2026 & 2032
    • TABLE 149: UK Recent Past, Current & Future Analysis for Tinea Pedis (Athlete's Foot) Treatment by Administration Route - Oral Administration Route and Topical Administration Route - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 150: UK Historic Review for Tinea Pedis (Athlete's Foot) Treatment by Administration Route - Oral Administration Route and Topical Administration Route Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 151: UK 13-Year Perspective for Tinea Pedis (Athlete's Foot) Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration Route and Topical Administration Route for the Years 2020, 2026 & 2032
  • SPAIN
    • TABLE 152: Spain Recent Past, Current & Future Analysis for Tinea Pedis (Athlete's Foot) Treatment by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 153: Spain Historic Review for Tinea Pedis (Athlete's Foot) Treatment by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 154: Spain 13-Year Perspective for Tinea Pedis (Athlete's Foot) Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Distribution Channel for the Years 2020, 2026 & 2032
    • TABLE 155: Spain Recent Past, Current & Future Analysis for Tinea Pedis (Athlete's Foot) Treatment by Drug Class - Azoles Drug Class, Allylamines / Benzylamines Drug Class, Polyenes Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 156: Spain Historic Review for Tinea Pedis (Athlete's Foot) Treatment by Drug Class - Azoles Drug Class, Allylamines / Benzylamines Drug Class, Polyenes Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 157: Spain 13-Year Perspective for Tinea Pedis (Athlete's Foot) Treatment by Drug Class - Percentage Breakdown of Value Sales for Azoles Drug Class, Allylamines / Benzylamines Drug Class, Polyenes Drug Class and Other Drug Classes for the Years 2020, 2026 & 2032
    • TABLE 158: Spain Recent Past, Current & Future Analysis for Tinea Pedis (Athlete's Foot) Treatment by Disease - Interdigital Tinea Pedis Disease, Plantar Disease and Vesicular / Inflammatory Disease - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 159: Spain Historic Review for Tinea Pedis (Athlete's Foot) Treatment by Disease - Interdigital Tinea Pedis Disease, Plantar Disease and Vesicular / Inflammatory Disease Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 160: Spain 13-Year Perspective for Tinea Pedis (Athlete's Foot) Treatment by Disease - Percentage Breakdown of Value Sales for Interdigital Tinea Pedis Disease, Plantar Disease and Vesicular / Inflammatory Disease for the Years 2020, 2026 & 2032
    • TABLE 161: Spain Recent Past, Current & Future Analysis for Tinea Pedis (Athlete's Foot) Treatment by Administration Route - Oral Administration Route and Topical Administration Route - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 162: Spain Historic Review for Tinea Pedis (Athlete's Foot) Treatment by Administration Route - Oral Administration Route and Topical Administration Route Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 163: Spain 13-Year Perspective for Tinea Pedis (Athlete's Foot) Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration Route and Topical Administration Route for the Years 2020, 2026 & 2032
  • RUSSIA
    • TABLE 164: Russia Recent Past, Current & Future Analysis for Tinea Pedis (Athlete's Foot) Treatment by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 165: Russia Historic Review for Tinea Pedis (Athlete's Foot) Treatment by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 166: Russia 13-Year Perspective for Tinea Pedis (Athlete's Foot) Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Distribution Channel for the Years 2020, 2026 & 2032
    • TABLE 167: Russia Recent Past, Current & Future Analysis for Tinea Pedis (Athlete's Foot) Treatment by Drug Class - Azoles Drug Class, Allylamines / Benzylamines Drug Class, Polyenes Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 168: Russia Historic Review for Tinea Pedis (Athlete's Foot) Treatment by Drug Class - Azoles Drug Class, Allylamines / Benzylamines Drug Class, Polyenes Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 169: Russia 13-Year Perspective for Tinea Pedis (Athlete's Foot) Treatment by Drug Class - Percentage Breakdown of Value Sales for Azoles Drug Class, Allylamines / Benzylamines Drug Class, Polyenes Drug Class and Other Drug Classes for the Years 2020, 2026 & 2032
    • TABLE 170: Russia Recent Past, Current & Future Analysis for Tinea Pedis (Athlete's Foot) Treatment by Disease - Interdigital Tinea Pedis Disease, Plantar Disease and Vesicular / Inflammatory Disease - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 171: Russia Historic Review for Tinea Pedis (Athlete's Foot) Treatment by Disease - Interdigital Tinea Pedis Disease, Plantar Disease and Vesicular / Inflammatory Disease Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 172: Russia 13-Year Perspective for Tinea Pedis (Athlete's Foot) Treatment by Disease - Percentage Breakdown of Value Sales for Interdigital Tinea Pedis Disease, Plantar Disease and Vesicular / Inflammatory Disease for the Years 2020, 2026 & 2032
    • TABLE 173: Russia Recent Past, Current & Future Analysis for Tinea Pedis (Athlete's Foot) Treatment by Administration Route - Oral Administration Route and Topical Administration Route - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 174: Russia Historic Review for Tinea Pedis (Athlete's Foot) Treatment by Administration Route - Oral Administration Route and Topical Administration Route Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 175: Russia 13-Year Perspective for Tinea Pedis (Athlete's Foot) Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration Route and Topical Administration Route for the Years 2020, 2026 & 2032
  • REST OF EUROPE
    • TABLE 176: Rest of Europe Recent Past, Current & Future Analysis for Tinea Pedis (Athlete's Foot) Treatment by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 177: Rest of Europe Historic Review for Tinea Pedis (Athlete's Foot) Treatment by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 178: Rest of Europe 13-Year Perspective for Tinea Pedis (Athlete's Foot) Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Distribution Channel for the Years 2020, 2026 & 2032
    • TABLE 179: Rest of Europe Recent Past, Current & Future Analysis for Tinea Pedis (Athlete's Foot) Treatment by Drug Class - Azoles Drug Class, Allylamines / Benzylamines Drug Class, Polyenes Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 180: Rest of Europe Historic Review for Tinea Pedis (Athlete's Foot) Treatment by Drug Class - Azoles Drug Class, Allylamines / Benzylamines Drug Class, Polyenes Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 181: Rest of Europe 13-Year Perspective for Tinea Pedis (Athlete's Foot) Treatment by Drug Class - Percentage Breakdown of Value Sales for Azoles Drug Class, Allylamines / Benzylamines Drug Class, Polyenes Drug Class and Other Drug Classes for the Years 2020, 2026 & 2032
    • TABLE 182: Rest of Europe Recent Past, Current & Future Analysis for Tinea Pedis (Athlete's Foot) Treatment by Disease - Interdigital Tinea Pedis Disease, Plantar Disease and Vesicular / Inflammatory Disease - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 183: Rest of Europe Historic Review for Tinea Pedis (Athlete's Foot) Treatment by Disease - Interdigital Tinea Pedis Disease, Plantar Disease and Vesicular / Inflammatory Disease Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 184: Rest of Europe 13-Year Perspective for Tinea Pedis (Athlete's Foot) Treatment by Disease - Percentage Breakdown of Value Sales for Interdigital Tinea Pedis Disease, Plantar Disease and Vesicular / Inflammatory Disease for the Years 2020, 2026 & 2032
    • TABLE 185: Rest of Europe Recent Past, Current & Future Analysis for Tinea Pedis (Athlete's Foot) Treatment by Administration Route - Oral Administration Route and Topical Administration Route - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 186: Rest of Europe Historic Review for Tinea Pedis (Athlete's Foot) Treatment by Administration Route - Oral Administration Route and Topical Administration Route Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 187: Rest of Europe 13-Year Perspective for Tinea Pedis (Athlete's Foot) Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration Route and Topical Administration Route for the Years 2020, 2026 & 2032
  • ASIA-PACIFIC
    • Tinea Pedis (Athlete's Foot) Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2026 (E)
    • TABLE 188: Asia-Pacific Recent Past, Current & Future Analysis for Tinea Pedis (Athlete's Foot) Treatment by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2025 through 2032 and % CAGR
    • TABLE 189: Asia-Pacific Historic Review for Tinea Pedis (Athlete's Foot) Treatment by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 190: Asia-Pacific 13-Year Perspective for Tinea Pedis (Athlete's Foot) Treatment by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2020, 2026 & 2032
    • TABLE 191: Asia-Pacific Recent Past, Current & Future Analysis for Tinea Pedis (Athlete's Foot) Treatment by Drug Class - Azoles Drug Class, Allylamines / Benzylamines Drug Class, Polyenes Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 192: Asia-Pacific Historic Review for Tinea Pedis (Athlete's Foot) Treatment by Drug Class - Azoles Drug Class, Allylamines / Benzylamines Drug Class, Polyenes Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 193: Asia-Pacific 13-Year Perspective for Tinea Pedis (Athlete's Foot) Treatment by Drug Class - Percentage Breakdown of Value Sales for Azoles Drug Class, Allylamines / Benzylamines Drug Class, Polyenes Drug Class and Other Drug Classes for the Years 2020, 2026 & 2032
    • TABLE 194: Asia-Pacific Recent Past, Current & Future Analysis for Tinea Pedis (Athlete's Foot) Treatment by Disease - Interdigital Tinea Pedis Disease, Plantar Disease and Vesicular / Inflammatory Disease - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 195: Asia-Pacific Historic Review for Tinea Pedis (Athlete's Foot) Treatment by Disease - Interdigital Tinea Pedis Disease, Plantar Disease and Vesicular / Inflammatory Disease Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 196: Asia-Pacific 13-Year Perspective for Tinea Pedis (Athlete's Foot) Treatment by Disease - Percentage Breakdown of Value Sales for Interdigital Tinea Pedis Disease, Plantar Disease and Vesicular / Inflammatory Disease for the Years 2020, 2026 & 2032
    • TABLE 197: Asia-Pacific Recent Past, Current & Future Analysis for Tinea Pedis (Athlete's Foot) Treatment by Administration Route - Oral Administration Route and Topical Administration Route - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 198: Asia-Pacific Historic Review for Tinea Pedis (Athlete's Foot) Treatment by Administration Route - Oral Administration Route and Topical Administration Route Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 199: Asia-Pacific 13-Year Perspective for Tinea Pedis (Athlete's Foot) Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration Route and Topical Administration Route for the Years 2020, 2026 & 2032
    • TABLE 200: Asia-Pacific Recent Past, Current & Future Analysis for Tinea Pedis (Athlete's Foot) Treatment by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 201: Asia-Pacific Historic Review for Tinea Pedis (Athlete's Foot) Treatment by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 202: Asia-Pacific 13-Year Perspective for Tinea Pedis (Athlete's Foot) Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Distribution Channel for the Years 2020, 2026 & 2032
  • AUSTRALIA
    • Tinea Pedis (Athlete's Foot) Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2026 (E)
    • TABLE 203: Australia Recent Past, Current & Future Analysis for Tinea Pedis (Athlete's Foot) Treatment by Drug Class - Azoles Drug Class, Allylamines / Benzylamines Drug Class, Polyenes Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 204: Australia Historic Review for Tinea Pedis (Athlete's Foot) Treatment by Drug Class - Azoles Drug Class, Allylamines / Benzylamines Drug Class, Polyenes Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 205: Australia 13-Year Perspective for Tinea Pedis (Athlete's Foot) Treatment by Drug Class - Percentage Breakdown of Value Sales for Azoles Drug Class, Allylamines / Benzylamines Drug Class, Polyenes Drug Class and Other Drug Classes for the Years 2020, 2026 & 2032
    • TABLE 206: Australia Recent Past, Current & Future Analysis for Tinea Pedis (Athlete's Foot) Treatment by Disease - Interdigital Tinea Pedis Disease, Plantar Disease and Vesicular / Inflammatory Disease - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 207: Australia Historic Review for Tinea Pedis (Athlete's Foot) Treatment by Disease - Interdigital Tinea Pedis Disease, Plantar Disease and Vesicular / Inflammatory Disease Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 208: Australia 13-Year Perspective for Tinea Pedis (Athlete's Foot) Treatment by Disease - Percentage Breakdown of Value Sales for Interdigital Tinea Pedis Disease, Plantar Disease and Vesicular / Inflammatory Disease for the Years 2020, 2026 & 2032
    • TABLE 209: Australia Recent Past, Current & Future Analysis for Tinea Pedis (Athlete's Foot) Treatment by Administration Route - Oral Administration Route and Topical Administration Route - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 210: Australia Historic Review for Tinea Pedis (Athlete's Foot) Treatment by Administration Route - Oral Administration Route and Topical Administration Route Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 211: Australia 13-Year Perspective for Tinea Pedis (Athlete's Foot) Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration Route and Topical Administration Route for the Years 2020, 2026 & 2032
    • TABLE 212: Australia Recent Past, Current & Future Analysis for Tinea Pedis (Athlete's Foot) Treatment by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 213: Australia Historic Review for Tinea Pedis (Athlete's Foot) Treatment by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 214: Australia 13-Year Perspective for Tinea Pedis (Athlete's Foot) Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Distribution Channel for the Years 2020, 2026 & 2032
  • INDIA
    • Tinea Pedis (Athlete's Foot) Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2026 (E)
    • TABLE 215: India Recent Past, Current & Future Analysis for Tinea Pedis (Athlete's Foot) Treatment by Drug Class - Azoles Drug Class, Allylamines / Benzylamines Drug Class, Polyenes Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 216: India Historic Review for Tinea Pedis (Athlete's Foot) Treatment by Drug Class - Azoles Drug Class, Allylamines / Benzylamines Drug Class, Polyenes Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 217: India 13-Year Perspective for Tinea Pedis (Athlete's Foot) Treatment by Drug Class - Percentage Breakdown of Value Sales for Azoles Drug Class, Allylamines / Benzylamines Drug Class, Polyenes Drug Class and Other Drug Classes for the Years 2020, 2026 & 2032
    • TABLE 218: India Recent Past, Current & Future Analysis for Tinea Pedis (Athlete's Foot) Treatment by Disease - Interdigital Tinea Pedis Disease, Plantar Disease and Vesicular / Inflammatory Disease - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 219: India Historic Review for Tinea Pedis (Athlete's Foot) Treatment by Disease - Interdigital Tinea Pedis Disease, Plantar Disease and Vesicular / Inflammatory Disease Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 220: India 13-Year Perspective for Tinea Pedis (Athlete's Foot) Treatment by Disease - Percentage Breakdown of Value Sales for Interdigital Tinea Pedis Disease, Plantar Disease and Vesicular / Inflammatory Disease for the Years 2020, 2026 & 2032
    • TABLE 221: India Recent Past, Current & Future Analysis for Tinea Pedis (Athlete's Foot) Treatment by Administration Route - Oral Administration Route and Topical Administration Route - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 222: India Historic Review for Tinea Pedis (Athlete's Foot) Treatment by Administration Route - Oral Administration Route and Topical Administration Route Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 223: India 13-Year Perspective for Tinea Pedis (Athlete's Foot) Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration Route and Topical Administration Route for the Years 2020, 2026 & 2032
    • TABLE 224: India Recent Past, Current & Future Analysis for Tinea Pedis (Athlete's Foot) Treatment by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 225: India Historic Review for Tinea Pedis (Athlete's Foot) Treatment by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 226: India 13-Year Perspective for Tinea Pedis (Athlete's Foot) Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Distribution Channel for the Years 2020, 2026 & 2032
  • SOUTH KOREA
    • TABLE 227: South Korea Recent Past, Current & Future Analysis for Tinea Pedis (Athlete's Foot) Treatment by Drug Class - Azoles Drug Class, Allylamines / Benzylamines Drug Class, Polyenes Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 228: South Korea Historic Review for Tinea Pedis (Athlete's Foot) Treatment by Drug Class - Azoles Drug Class, Allylamines / Benzylamines Drug Class, Polyenes Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 229: South Korea 13-Year Perspective for Tinea Pedis (Athlete's Foot) Treatment by Drug Class - Percentage Breakdown of Value Sales for Azoles Drug Class, Allylamines / Benzylamines Drug Class, Polyenes Drug Class and Other Drug Classes for the Years 2020, 2026 & 2032
    • TABLE 230: South Korea Recent Past, Current & Future Analysis for Tinea Pedis (Athlete's Foot) Treatment by Disease - Interdigital Tinea Pedis Disease, Plantar Disease and Vesicular / Inflammatory Disease - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 231: South Korea Historic Review for Tinea Pedis (Athlete's Foot) Treatment by Disease - Interdigital Tinea Pedis Disease, Plantar Disease and Vesicular / Inflammatory Disease Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 232: South Korea 13-Year Perspective for Tinea Pedis (Athlete's Foot) Treatment by Disease - Percentage Breakdown of Value Sales for Interdigital Tinea Pedis Disease, Plantar Disease and Vesicular / Inflammatory Disease for the Years 2020, 2026 & 2032
    • TABLE 233: South Korea Recent Past, Current & Future Analysis for Tinea Pedis (Athlete's Foot) Treatment by Administration Route - Oral Administration Route and Topical Administration Route - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 234: South Korea Historic Review for Tinea Pedis (Athlete's Foot) Treatment by Administration Route - Oral Administration Route and Topical Administration Route Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 235: South Korea 13-Year Perspective for Tinea Pedis (Athlete's Foot) Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration Route and Topical Administration Route for the Years 2020, 2026 & 2032
    • TABLE 236: South Korea Recent Past, Current & Future Analysis for Tinea Pedis (Athlete's Foot) Treatment by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 237: South Korea Historic Review for Tinea Pedis (Athlete's Foot) Treatment by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 238: South Korea 13-Year Perspective for Tinea Pedis (Athlete's Foot) Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Distribution Channel for the Years 2020, 2026 & 2032
  • REST OF ASIA-PACIFIC
    • TABLE 239: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Tinea Pedis (Athlete's Foot) Treatment by Drug Class - Azoles Drug Class, Allylamines / Benzylamines Drug Class, Polyenes Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 240: Rest of Asia-Pacific Historic Review for Tinea Pedis (Athlete's Foot) Treatment by Drug Class - Azoles Drug Class, Allylamines / Benzylamines Drug Class, Polyenes Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 241: Rest of Asia-Pacific 13-Year Perspective for Tinea Pedis (Athlete's Foot) Treatment by Drug Class - Percentage Breakdown of Value Sales for Azoles Drug Class, Allylamines / Benzylamines Drug Class, Polyenes Drug Class and Other Drug Classes for the Years 2020, 2026 & 2032
    • TABLE 242: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Tinea Pedis (Athlete's Foot) Treatment by Disease - Interdigital Tinea Pedis Disease, Plantar Disease and Vesicular / Inflammatory Disease - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 243: Rest of Asia-Pacific Historic Review for Tinea Pedis (Athlete's Foot) Treatment by Disease - Interdigital Tinea Pedis Disease, Plantar Disease and Vesicular / Inflammatory Disease Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 244: Rest of Asia-Pacific 13-Year Perspective for Tinea Pedis (Athlete's Foot) Treatment by Disease - Percentage Breakdown of Value Sales for Interdigital Tinea Pedis Disease, Plantar Disease and Vesicular / Inflammatory Disease for the Years 2020, 2026 & 2032
    • TABLE 245: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Tinea Pedis (Athlete's Foot) Treatment by Administration Route - Oral Administration Route and Topical Administration Route - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 246: Rest of Asia-Pacific Historic Review for Tinea Pedis (Athlete's Foot) Treatment by Administration Route - Oral Administration Route and Topical Administration Route Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 247: Rest of Asia-Pacific 13-Year Perspective for Tinea Pedis (Athlete's Foot) Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration Route and Topical Administration Route for the Years 2020, 2026 & 2032
    • TABLE 248: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Tinea Pedis (Athlete's Foot) Treatment by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 249: Rest of Asia-Pacific Historic Review for Tinea Pedis (Athlete's Foot) Treatment by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 250: Rest of Asia-Pacific 13-Year Perspective for Tinea Pedis (Athlete's Foot) Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Distribution Channel for the Years 2020, 2026 & 2032
  • LATIN AMERICA
    • Tinea Pedis (Athlete's Foot) Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2026 (E)
    • TABLE 251: Latin America Recent Past, Current & Future Analysis for Tinea Pedis (Athlete's Foot) Treatment by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 252: Latin America Historic Review for Tinea Pedis (Athlete's Foot) Treatment by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 253: Latin America 13-Year Perspective for Tinea Pedis (Athlete's Foot) Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Distribution Channel for the Years 2020, 2026 & 2032
    • TABLE 254: Latin America Recent Past, Current & Future Analysis for Tinea Pedis (Athlete's Foot) Treatment by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2025 through 2032 and % CAGR
    • TABLE 255: Latin America Historic Review for Tinea Pedis (Athlete's Foot) Treatment by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 256: Latin America 13-Year Perspective for Tinea Pedis (Athlete's Foot) Treatment by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2020, 2026 & 2032
    • TABLE 257: Latin America Recent Past, Current & Future Analysis for Tinea Pedis (Athlete's Foot) Treatment by Drug Class - Azoles Drug Class, Allylamines / Benzylamines Drug Class, Polyenes Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 258: Latin America Historic Review for Tinea Pedis (Athlete's Foot) Treatment by Drug Class - Azoles Drug Class, Allylamines / Benzylamines Drug Class, Polyenes Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 259: Latin America 13-Year Perspective for Tinea Pedis (Athlete's Foot) Treatment by Drug Class - Percentage Breakdown of Value Sales for Azoles Drug Class, Allylamines / Benzylamines Drug Class, Polyenes Drug Class and Other Drug Classes for the Years 2020, 2026 & 2032
    • TABLE 260: Latin America Recent Past, Current & Future Analysis for Tinea Pedis (Athlete's Foot) Treatment by Disease - Interdigital Tinea Pedis Disease, Plantar Disease and Vesicular / Inflammatory Disease - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 261: Latin America Historic Review for Tinea Pedis (Athlete's Foot) Treatment by Disease - Interdigital Tinea Pedis Disease, Plantar Disease and Vesicular / Inflammatory Disease Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 262: Latin America 13-Year Perspective for Tinea Pedis (Athlete's Foot) Treatment by Disease - Percentage Breakdown of Value Sales for Interdigital Tinea Pedis Disease, Plantar Disease and Vesicular / Inflammatory Disease for the Years 2020, 2026 & 2032
    • TABLE 263: Latin America Recent Past, Current & Future Analysis for Tinea Pedis (Athlete's Foot) Treatment by Administration Route - Oral Administration Route and Topical Administration Route - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 264: Latin America Historic Review for Tinea Pedis (Athlete's Foot) Treatment by Administration Route - Oral Administration Route and Topical Administration Route Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 265: Latin America 13-Year Perspective for Tinea Pedis (Athlete's Foot) Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration Route and Topical Administration Route for the Years 2020, 2026 & 2032
  • ARGENTINA
    • TABLE 266: Argentina Recent Past, Current & Future Analysis for Tinea Pedis (Athlete's Foot) Treatment by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 267: Argentina Historic Review for Tinea Pedis (Athlete's Foot) Treatment by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 268: Argentina 13-Year Perspective for Tinea Pedis (Athlete's Foot) Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Distribution Channel for the Years 2020, 2026 & 2032
    • TABLE 269: Argentina Recent Past, Current & Future Analysis for Tinea Pedis (Athlete's Foot) Treatment by Drug Class - Azoles Drug Class, Allylamines / Benzylamines Drug Class, Polyenes Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 270: Argentina Historic Review for Tinea Pedis (Athlete's Foot) Treatment by Drug Class - Azoles Drug Class, Allylamines / Benzylamines Drug Class, Polyenes Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 271: Argentina 13-Year Perspective for Tinea Pedis (Athlete's Foot) Treatment by Drug Class - Percentage Breakdown of Value Sales for Azoles Drug Class, Allylamines / Benzylamines Drug Class, Polyenes Drug Class and Other Drug Classes for the Years 2020, 2026 & 2032
    • TABLE 272: Argentina Recent Past, Current & Future Analysis for Tinea Pedis (Athlete's Foot) Treatment by Disease - Interdigital Tinea Pedis Disease, Plantar Disease and Vesicular / Inflammatory Disease - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 273: Argentina Historic Review for Tinea Pedis (Athlete's Foot) Treatment by Disease - Interdigital Tinea Pedis Disease, Plantar Disease and Vesicular / Inflammatory Disease Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 274: Argentina 13-Year Perspective for Tinea Pedis (Athlete's Foot) Treatment by Disease - Percentage Breakdown of Value Sales for Interdigital Tinea Pedis Disease, Plantar Disease and Vesicular / Inflammatory Disease for the Years 2020, 2026 & 2032
    • TABLE 275: Argentina Recent Past, Current & Future Analysis for Tinea Pedis (Athlete's Foot) Treatment by Administration Route - Oral Administration Route and Topical Administration Route - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 276: Argentina Historic Review for Tinea Pedis (Athlete's Foot) Treatment by Administration Route - Oral Administration Route and Topical Administration Route Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 277: Argentina 13-Year Perspective for Tinea Pedis (Athlete's Foot) Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration Route and Topical Administration Route for the Years 2020, 2026 & 2032
  • BRAZIL
    • TABLE 278: Brazil Recent Past, Current & Future Analysis for Tinea Pedis (Athlete's Foot) Treatment by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 279: Brazil Historic Review for Tinea Pedis (Athlete's Foot) Treatment by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 280: Brazil 13-Year Perspective for Tinea Pedis (Athlete's Foot) Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Distribution Channel for the Years 2020, 2026 & 2032
    • TABLE 281: Brazil Recent Past, Current & Future Analysis for Tinea Pedis (Athlete's Foot) Treatment by Drug Class - Azoles Drug Class, Allylamines / Benzylamines Drug Class, Polyenes Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 282: Brazil Historic Review for Tinea Pedis (Athlete's Foot) Treatment by Drug Class - Azoles Drug Class, Allylamines / Benzylamines Drug Class, Polyenes Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 283: Brazil 13-Year Perspective for Tinea Pedis (Athlete's Foot) Treatment by Drug Class - Percentage Breakdown of Value Sales for Azoles Drug Class, Allylamines / Benzylamines Drug Class, Polyenes Drug Class and Other Drug Classes for the Years 2020, 2026 & 2032
    • TABLE 284: Brazil Recent Past, Current & Future Analysis for Tinea Pedis (Athlete's Foot) Treatment by Disease - Interdigital Tinea Pedis Disease, Plantar Disease and Vesicular / Inflammatory Disease - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 285: Brazil Historic Review for Tinea Pedis (Athlete's Foot) Treatment by Disease - Interdigital Tinea Pedis Disease, Plantar Disease and Vesicular / Inflammatory Disease Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 286: Brazil 13-Year Perspective for Tinea Pedis (Athlete's Foot) Treatment by Disease - Percentage Breakdown of Value Sales for Interdigital Tinea Pedis Disease, Plantar Disease and Vesicular / Inflammatory Disease for the Years 2020, 2026 & 2032
    • TABLE 287: Brazil Recent Past, Current & Future Analysis for Tinea Pedis (Athlete's Foot) Treatment by Administration Route - Oral Administration Route and Topical Administration Route - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 288: Brazil Historic Review for Tinea Pedis (Athlete's Foot) Treatment by Administration Route - Oral Administration Route and Topical Administration Route Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 289: Brazil 13-Year Perspective for Tinea Pedis (Athlete's Foot) Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration Route and Topical Administration Route for the Years 2020, 2026 & 2032
  • MEXICO
    • TABLE 290: Mexico Recent Past, Current & Future Analysis for Tinea Pedis (Athlete's Foot) Treatment by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 291: Mexico Historic Review for Tinea Pedis (Athlete's Foot) Treatment by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 292: Mexico 13-Year Perspective for Tinea Pedis (Athlete's Foot) Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Distribution Channel for the Years 2020, 2026 & 2032
    • TABLE 293: Mexico Recent Past, Current & Future Analysis for Tinea Pedis (Athlete's Foot) Treatment by Drug Class - Azoles Drug Class, Allylamines / Benzylamines Drug Class, Polyenes Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 294: Mexico Historic Review for Tinea Pedis (Athlete's Foot) Treatment by Drug Class - Azoles Drug Class, Allylamines / Benzylamines Drug Class, Polyenes Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 295: Mexico 13-Year Perspective for Tinea Pedis (Athlete's Foot) Treatment by Drug Class - Percentage Breakdown of Value Sales for Azoles Drug Class, Allylamines / Benzylamines Drug Class, Polyenes Drug Class and Other Drug Classes for the Years 2020, 2026 & 2032
    • TABLE 296: Mexico Recent Past, Current & Future Analysis for Tinea Pedis (Athlete's Foot) Treatment by Disease - Interdigital Tinea Pedis Disease, Plantar Disease and Vesicular / Inflammatory Disease - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 297: Mexico Historic Review for Tinea Pedis (Athlete's Foot) Treatment by Disease - Interdigital Tinea Pedis Disease, Plantar Disease and Vesicular / Inflammatory Disease Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 298: Mexico 13-Year Perspective for Tinea Pedis (Athlete's Foot) Treatment by Disease - Percentage Breakdown of Value Sales for Interdigital Tinea Pedis Disease, Plantar Disease and Vesicular / Inflammatory Disease for the Years 2020, 2026 & 2032
    • TABLE 299: Mexico Recent Past, Current & Future Analysis for Tinea Pedis (Athlete's Foot) Treatment by Administration Route - Oral Administration Route and Topical Administration Route - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 300: Mexico Historic Review for Tinea Pedis (Athlete's Foot) Treatment by Administration Route - Oral Administration Route and Topical Administration Route Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 301: Mexico 13-Year Perspective for Tinea Pedis (Athlete's Foot) Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration Route and Topical Administration Route for the Years 2020, 2026 & 2032
  • REST OF LATIN AMERICA
    • TABLE 302: Rest of Latin America Recent Past, Current & Future Analysis for Tinea Pedis (Athlete's Foot) Treatment by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 303: Rest of Latin America Historic Review for Tinea Pedis (Athlete's Foot) Treatment by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 304: Rest of Latin America 13-Year Perspective for Tinea Pedis (Athlete's Foot) Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Distribution Channel for the Years 2020, 2026 & 2032
    • TABLE 305: Rest of Latin America Recent Past, Current & Future Analysis for Tinea Pedis (Athlete's Foot) Treatment by Drug Class - Azoles Drug Class, Allylamines / Benzylamines Drug Class, Polyenes Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 306: Rest of Latin America Historic Review for Tinea Pedis (Athlete's Foot) Treatment by Drug Class - Azoles Drug Class, Allylamines / Benzylamines Drug Class, Polyenes Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 307: Rest of Latin America 13-Year Perspective for Tinea Pedis (Athlete's Foot) Treatment by Drug Class - Percentage Breakdown of Value Sales for Azoles Drug Class, Allylamines / Benzylamines Drug Class, Polyenes Drug Class and Other Drug Classes for the Years 2020, 2026 & 2032
    • TABLE 308: Rest of Latin America Recent Past, Current & Future Analysis for Tinea Pedis (Athlete's Foot) Treatment by Disease - Interdigital Tinea Pedis Disease, Plantar Disease and Vesicular / Inflammatory Disease - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 309: Rest of Latin America Historic Review for Tinea Pedis (Athlete's Foot) Treatment by Disease - Interdigital Tinea Pedis Disease, Plantar Disease and Vesicular / Inflammatory Disease Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 310: Rest of Latin America 13-Year Perspective for Tinea Pedis (Athlete's Foot) Treatment by Disease - Percentage Breakdown of Value Sales for Interdigital Tinea Pedis Disease, Plantar Disease and Vesicular / Inflammatory Disease for the Years 2020, 2026 & 2032
    • TABLE 311: Rest of Latin America Recent Past, Current & Future Analysis for Tinea Pedis (Athlete's Foot) Treatment by Administration Route - Oral Administration Route and Topical Administration Route - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 312: Rest of Latin America Historic Review for Tinea Pedis (Athlete's Foot) Treatment by Administration Route - Oral Administration Route and Topical Administration Route Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 313: Rest of Latin America 13-Year Perspective for Tinea Pedis (Athlete's Foot) Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration Route and Topical Administration Route for the Years 2020, 2026 & 2032
  • MIDDLE EAST
    • Tinea Pedis (Athlete's Foot) Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2026 (E)
    • TABLE 314: Middle East Recent Past, Current & Future Analysis for Tinea Pedis (Athlete's Foot) Treatment by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 315: Middle East Historic Review for Tinea Pedis (Athlete's Foot) Treatment by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 316: Middle East 13-Year Perspective for Tinea Pedis (Athlete's Foot) Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Distribution Channel for the Years 2020, 2026 & 2032
    • TABLE 317: Middle East Recent Past, Current & Future Analysis for Tinea Pedis (Athlete's Foot) Treatment by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2025 through 2032 and % CAGR
    • TABLE 318: Middle East Historic Review for Tinea Pedis (Athlete's Foot) Treatment by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 319: Middle East 13-Year Perspective for Tinea Pedis (Athlete's Foot) Treatment by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2020, 2026 & 2032
    • TABLE 320: Middle East Recent Past, Current & Future Analysis for Tinea Pedis (Athlete's Foot) Treatment by Drug Class - Azoles Drug Class, Allylamines / Benzylamines Drug Class, Polyenes Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 321: Middle East Historic Review for Tinea Pedis (Athlete's Foot) Treatment by Drug Class - Azoles Drug Class, Allylamines / Benzylamines Drug Class, Polyenes Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 322: Middle East 13-Year Perspective for Tinea Pedis (Athlete's Foot) Treatment by Drug Class - Percentage Breakdown of Value Sales for Azoles Drug Class, Allylamines / Benzylamines Drug Class, Polyenes Drug Class and Other Drug Classes for the Years 2020, 2026 & 2032
    • TABLE 323: Middle East Recent Past, Current & Future Analysis for Tinea Pedis (Athlete's Foot) Treatment by Disease - Interdigital Tinea Pedis Disease, Plantar Disease and Vesicular / Inflammatory Disease - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 324: Middle East Historic Review for Tinea Pedis (Athlete's Foot) Treatment by Disease - Interdigital Tinea Pedis Disease, Plantar Disease and Vesicular / Inflammatory Disease Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 325: Middle East 13-Year Perspective for Tinea Pedis (Athlete's Foot) Treatment by Disease - Percentage Breakdown of Value Sales for Interdigital Tinea Pedis Disease, Plantar Disease and Vesicular / Inflammatory Disease for the Years 2020, 2026 & 2032
    • TABLE 326: Middle East Recent Past, Current & Future Analysis for Tinea Pedis (Athlete's Foot) Treatment by Administration Route - Oral Administration Route and Topical Administration Route - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 327: Middle East Historic Review for Tinea Pedis (Athlete's Foot) Treatment by Administration Route - Oral Administration Route and Topical Administration Route Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 328: Middle East 13-Year Perspective for Tinea Pedis (Athlete's Foot) Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration Route and Topical Administration Route for the Years 2020, 2026 & 2032
  • IRAN
    • TABLE 329: Iran Recent Past, Current & Future Analysis for Tinea Pedis (Athlete's Foot) Treatment by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 330: Iran Historic Review for Tinea Pedis (Athlete's Foot) Treatment by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 331: Iran 13-Year Perspective for Tinea Pedis (Athlete's Foot) Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Distribution Channel for the Years 2020, 2026 & 2032
    • TABLE 332: Iran Recent Past, Current & Future Analysis for Tinea Pedis (Athlete's Foot) Treatment by Drug Class - Azoles Drug Class, Allylamines / Benzylamines Drug Class, Polyenes Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 333: Iran Historic Review for Tinea Pedis (Athlete's Foot) Treatment by Drug Class - Azoles Drug Class, Allylamines / Benzylamines Drug Class, Polyenes Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 334: Iran 13-Year Perspective for Tinea Pedis (Athlete's Foot) Treatment by Drug Class - Percentage Breakdown of Value Sales for Azoles Drug Class, Allylamines / Benzylamines Drug Class, Polyenes Drug Class and Other Drug Classes for the Years 2020, 2026 & 2032
    • TABLE 335: Iran Recent Past, Current & Future Analysis for Tinea Pedis (Athlete's Foot) Treatment by Disease - Interdigital Tinea Pedis Disease, Plantar Disease and Vesicular / Inflammatory Disease - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 336: Iran Historic Review for Tinea Pedis (Athlete's Foot) Treatment by Disease - Interdigital Tinea Pedis Disease, Plantar Disease and Vesicular / Inflammatory Disease Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 337: Iran 13-Year Perspective for Tinea Pedis (Athlete's Foot) Treatment by Disease - Percentage Breakdown of Value Sales for Interdigital Tinea Pedis Disease, Plantar Disease and Vesicular / Inflammatory Disease for the Years 2020, 2026 & 2032
    • TABLE 338: Iran Recent Past, Current & Future Analysis for Tinea Pedis (Athlete's Foot) Treatment by Administration Route - Oral Administration Route and Topical Administration Route - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 339: Iran Historic Review for Tinea Pedis (Athlete's Foot) Treatment by Administration Route - Oral Administration Route and Topical Administration Route Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 340: Iran 13-Year Perspective for Tinea Pedis (Athlete's Foot) Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration Route and Topical Administration Route for the Years 2020, 2026 & 2032
  • ISRAEL
    • TABLE 341: Israel Recent Past, Current & Future Analysis for Tinea Pedis (Athlete's Foot) Treatment by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 342: Israel Historic Review for Tinea Pedis (Athlete's Foot) Treatment by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 343: Israel 13-Year Perspective for Tinea Pedis (Athlete's Foot) Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Distribution Channel for the Years 2020, 2026 & 2032
    • TABLE 344: Israel Recent Past, Current & Future Analysis for Tinea Pedis (Athlete's Foot) Treatment by Drug Class - Azoles Drug Class, Allylamines / Benzylamines Drug Class, Polyenes Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 345: Israel Historic Review for Tinea Pedis (Athlete's Foot) Treatment by Drug Class - Azoles Drug Class, Allylamines / Benzylamines Drug Class, Polyenes Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 346: Israel 13-Year Perspective for Tinea Pedis (Athlete's Foot) Treatment by Drug Class - Percentage Breakdown of Value Sales for Azoles Drug Class, Allylamines / Benzylamines Drug Class, Polyenes Drug Class and Other Drug Classes for the Years 2020, 2026 & 2032
    • TABLE 347: Israel Recent Past, Current & Future Analysis for Tinea Pedis (Athlete's Foot) Treatment by Disease - Interdigital Tinea Pedis Disease, Plantar Disease and Vesicular / Inflammatory Disease - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 348: Israel Historic Review for Tinea Pedis (Athlete's Foot) Treatment by Disease - Interdigital Tinea Pedis Disease, Plantar Disease and Vesicular / Inflammatory Disease Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 349: Israel 13-Year Perspective for Tinea Pedis (Athlete's Foot) Treatment by Disease - Percentage Breakdown of Value Sales for Interdigital Tinea Pedis Disease, Plantar Disease and Vesicular / Inflammatory Disease for the Years 2020, 2026 & 2032
    • TABLE 350: Israel Recent Past, Current & Future Analysis for Tinea Pedis (Athlete's Foot) Treatment by Administration Route - Oral Administration Route and Topical Administration Route - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 351: Israel Historic Review for Tinea Pedis (Athlete's Foot) Treatment by Administration Route - Oral Administration Route and Topical Administration Route Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 352: Israel 13-Year Perspective for Tinea Pedis (Athlete's Foot) Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration Route and Topical Administration Route for the Years 2020, 2026 & 2032
  • SAUDI ARABIA
    • TABLE 353: Saudi Arabia Recent Past, Current & Future Analysis for Tinea Pedis (Athlete's Foot) Treatment by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 354: Saudi Arabia Historic Review for Tinea Pedis (Athlete's Foot) Treatment by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 355: Saudi Arabia 13-Year Perspective for Tinea Pedis (Athlete's Foot) Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Distribution Channel for the Years 2020, 2026 & 2032
    • TABLE 356: Saudi Arabia Recent Past, Current & Future Analysis for Tinea Pedis (Athlete's Foot) Treatment by Drug Class - Azoles Drug Class, Allylamines / Benzylamines Drug Class, Polyenes Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 357: Saudi Arabia Historic Review for Tinea Pedis (Athlete's Foot) Treatment by Drug Class - Azoles Drug Class, Allylamines / Benzylamines Drug Class, Polyenes Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 358: Saudi Arabia 13-Year Perspective for Tinea Pedis (Athlete's Foot) Treatment by Drug Class - Percentage Breakdown of Value Sales for Azoles Drug Class, Allylamines / Benzylamines Drug Class, Polyenes Drug Class and Other Drug Classes for the Years 2020, 2026 & 2032
    • TABLE 359: Saudi Arabia Recent Past, Current & Future Analysis for Tinea Pedis (Athlete's Foot) Treatment by Disease - Interdigital Tinea Pedis Disease, Plantar Disease and Vesicular / Inflammatory Disease - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 360: Saudi Arabia Historic Review for Tinea Pedis (Athlete's Foot) Treatment by Disease - Interdigital Tinea Pedis Disease, Plantar Disease and Vesicular / Inflammatory Disease Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 361: Saudi Arabia 13-Year Perspective for Tinea Pedis (Athlete's Foot) Treatment by Disease - Percentage Breakdown of Value Sales for Interdigital Tinea Pedis Disease, Plantar Disease and Vesicular / Inflammatory Disease for the Years 2020, 2026 & 2032
    • TABLE 362: Saudi Arabia Recent Past, Current & Future Analysis for Tinea Pedis (Athlete's Foot) Treatment by Administration Route - Oral Administration Route and Topical Administration Route - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 363: Saudi Arabia Historic Review for Tinea Pedis (Athlete's Foot) Treatment by Administration Route - Oral Administration Route and Topical Administration Route Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 364: Saudi Arabia 13-Year Perspective for Tinea Pedis (Athlete's Foot) Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration Route and Topical Administration Route for the Years 2020, 2026 & 2032
  • UNITED ARAB EMIRATES
    • TABLE 365: UAE Recent Past, Current & Future Analysis for Tinea Pedis (Athlete's Foot) Treatment by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 366: UAE Historic Review for Tinea Pedis (Athlete's Foot) Treatment by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 367: UAE 13-Year Perspective for Tinea Pedis (Athlete's Foot) Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Distribution Channel for the Years 2020, 2026 & 2032
    • TABLE 368: UAE Recent Past, Current & Future Analysis for Tinea Pedis (Athlete's Foot) Treatment by Drug Class - Azoles Drug Class, Allylamines / Benzylamines Drug Class, Polyenes Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 369: UAE Historic Review for Tinea Pedis (Athlete's Foot) Treatment by Drug Class - Azoles Drug Class, Allylamines / Benzylamines Drug Class, Polyenes Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 370: UAE 13-Year Perspective for Tinea Pedis (Athlete's Foot) Treatment by Drug Class - Percentage Breakdown of Value Sales for Azoles Drug Class, Allylamines / Benzylamines Drug Class, Polyenes Drug Class and Other Drug Classes for the Years 2020, 2026 & 2032
    • TABLE 371: UAE Recent Past, Current & Future Analysis for Tinea Pedis (Athlete's Foot) Treatment by Disease - Interdigital Tinea Pedis Disease, Plantar Disease and Vesicular / Inflammatory Disease - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 372: UAE Historic Review for Tinea Pedis (Athlete's Foot) Treatment by Disease - Interdigital Tinea Pedis Disease, Plantar Disease and Vesicular / Inflammatory Disease Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 373: UAE 13-Year Perspective for Tinea Pedis (Athlete's Foot) Treatment by Disease - Percentage Breakdown of Value Sales for Interdigital Tinea Pedis Disease, Plantar Disease and Vesicular / Inflammatory Disease for the Years 2020, 2026 & 2032
    • TABLE 374: UAE Recent Past, Current & Future Analysis for Tinea Pedis (Athlete's Foot) Treatment by Administration Route - Oral Administration Route and Topical Administration Route - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 375: UAE Historic Review for Tinea Pedis (Athlete's Foot) Treatment by Administration Route - Oral Administration Route and Topical Administration Route Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 376: UAE 13-Year Perspective for Tinea Pedis (Athlete's Foot) Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration Route and Topical Administration Route for the Years 2020, 2026 & 2032
  • REST OF MIDDLE EAST
    • TABLE 377: Rest of Middle East Recent Past, Current & Future Analysis for Tinea Pedis (Athlete's Foot) Treatment by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 378: Rest of Middle East Historic Review for Tinea Pedis (Athlete's Foot) Treatment by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 379: Rest of Middle East 13-Year Perspective for Tinea Pedis (Athlete's Foot) Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Distribution Channel for the Years 2020, 2026 & 2032
    • TABLE 380: Rest of Middle East Recent Past, Current & Future Analysis for Tinea Pedis (Athlete's Foot) Treatment by Drug Class - Azoles Drug Class, Allylamines / Benzylamines Drug Class, Polyenes Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 381: Rest of Middle East Historic Review for Tinea Pedis (Athlete's Foot) Treatment by Drug Class - Azoles Drug Class, Allylamines / Benzylamines Drug Class, Polyenes Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 382: Rest of Middle East 13-Year Perspective for Tinea Pedis (Athlete's Foot) Treatment by Drug Class - Percentage Breakdown of Value Sales for Azoles Drug Class, Allylamines / Benzylamines Drug Class, Polyenes Drug Class and Other Drug Classes for the Years 2020, 2026 & 2032
    • TABLE 383: Rest of Middle East Recent Past, Current & Future Analysis for Tinea Pedis (Athlete's Foot) Treatment by Disease - Interdigital Tinea Pedis Disease, Plantar Disease and Vesicular / Inflammatory Disease - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 384: Rest of Middle East Historic Review for Tinea Pedis (Athlete's Foot) Treatment by Disease - Interdigital Tinea Pedis Disease, Plantar Disease and Vesicular / Inflammatory Disease Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 385: Rest of Middle East 13-Year Perspective for Tinea Pedis (Athlete's Foot) Treatment by Disease - Percentage Breakdown of Value Sales for Interdigital Tinea Pedis Disease, Plantar Disease and Vesicular / Inflammatory Disease for the Years 2020, 2026 & 2032
    • TABLE 386: Rest of Middle East Recent Past, Current & Future Analysis for Tinea Pedis (Athlete's Foot) Treatment by Administration Route - Oral Administration Route and Topical Administration Route - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 387: Rest of Middle East Historic Review for Tinea Pedis (Athlete's Foot) Treatment by Administration Route - Oral Administration Route and Topical Administration Route Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 388: Rest of Middle East 13-Year Perspective for Tinea Pedis (Athlete's Foot) Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration Route and Topical Administration Route for the Years 2020, 2026 & 2032
  • AFRICA
    • Tinea Pedis (Athlete's Foot) Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2026 (E)
    • TABLE 389: Africa Recent Past, Current & Future Analysis for Tinea Pedis (Athlete's Foot) Treatment by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 390: Africa Historic Review for Tinea Pedis (Athlete's Foot) Treatment by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 391: Africa 13-Year Perspective for Tinea Pedis (Athlete's Foot) Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Distribution Channel for the Years 2020, 2026 & 2032
    • TABLE 392: Africa Recent Past, Current & Future Analysis for Tinea Pedis (Athlete's Foot) Treatment by Drug Class - Azoles Drug Class, Allylamines / Benzylamines Drug Class, Polyenes Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 393: Africa Historic Review for Tinea Pedis (Athlete's Foot) Treatment by Drug Class - Azoles Drug Class, Allylamines / Benzylamines Drug Class, Polyenes Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 394: Africa 13-Year Perspective for Tinea Pedis (Athlete's Foot) Treatment by Drug Class - Percentage Breakdown of Value Sales for Azoles Drug Class, Allylamines / Benzylamines Drug Class, Polyenes Drug Class and Other Drug Classes for the Years 2020, 2026 & 2032
    • TABLE 395: Africa Recent Past, Current & Future Analysis for Tinea Pedis (Athlete's Foot) Treatment by Disease - Interdigital Tinea Pedis Disease, Plantar Disease and Vesicular / Inflammatory Disease - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 396: Africa Historic Review for Tinea Pedis (Athlete's Foot) Treatment by Disease - Interdigital Tinea Pedis Disease, Plantar Disease and Vesicular / Inflammatory Disease Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 397: Africa 13-Year Perspective for Tinea Pedis (Athlete's Foot) Treatment by Disease - Percentage Breakdown of Value Sales for Interdigital Tinea Pedis Disease, Plantar Disease and Vesicular / Inflammatory Disease for the Years 2020, 2026 & 2032
    • TABLE 398: Africa Recent Past, Current & Future Analysis for Tinea Pedis (Athlete's Foot) Treatment by Administration Route - Oral Administration Route and Topical Administration Route - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 399: Africa Historic Review for Tinea Pedis (Athlete's Foot) Treatment by Administration Route - Oral Administration Route and Topical Administration Route Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 400: Africa 13-Year Perspective for Tinea Pedis (Athlete's Foot) Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration Route and Topical Administration Route for the Years 2020, 2026 & 2032

IV. COMPETITION

×

원하시는 정보를 찾아 드릴까요?

보안문자 새로고침
샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제
문의
원하시는 정보를
찾아 드릴까요?
문의주시면 필요한 정보를
신속하게 찾아드릴게요.
02-2025-2992
email
문의하기